Respiratory Syncytial Virus News and Research

RSS

Loyola uses FilmArray Respiratory Panel to screen infectious diseases

Cold, allergies, the flu or something else? Thanks to advanced technology, physicians at Loyola University Health System receive confirmation of their patient's respiratory illness within one hour. Loyola is one of only two hospitals in lllinois to use the FDA-approved FilmArray Respiratory Panel, which screens for 17 viral and 3 bacterial pathogens in about 60 minutes.

10 Jan 2013

Severe RSV disease may impair innate immune response in infants

Infants with severe lower respiratory tract infection caused by respiratory syncytial virus (RSV) may have a dysfunctional innate immune response that relates to the severity of their disease.

10 Dec 2012

Vaccinating families could protect young babies against RSV infection

Research by the University of Warwick indicates that vaccinating families could protect young babies against a common winter virus which can be fatal for infants under six months.

16 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Respiratory infections provide urban asthma clue

Urban infants have a different pattern of viral respiratory illness from suburban infants, which could help explain why they are more likely to develop asthma, say US researchers.

2 Oct 2012

Differences in viral illness patterns play a role in asthma development in urban, suburban children

Children living in low-income urban areas appear especially prone to developing asthma, possibly related to infections they acquire early in life. In a new study in The Journal of Infectious Diseases, available online, researchers from the University of Wisconsin in Madison investigated viral respiratory illnesses and their possible role in the development of asthma in urban versus suburban babies.

26 Sep 2012

NanoBio to present data from preclinical studies at 8th Annual International RSV Symposium

NanoBio Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.

25 Sep 2012

RSV virus selectively kills cancer cells

RSV, a virus that causes respiratory infections in infants and young children, selectively kills cancer cells while leaving healthy cells alone, researchers from the School of Medicine at The University of Texas Health Science Center San Antonio said.

7 Sep 2012

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

6 Sep 2012

Boosting immune system can help reduce asthma attacks due to viral infections

Details of a treatment that could help asthmatics fight infections that trigger 80% of asthma attacks, developed by University of Southampton spin-out company Synairgen, will be presented to European respiratory experts on Sunday 2 September.

1 Sep 2012

Vitamin D may help fight childhood acute respiratory infections

Supplementation with vitamin D, particularly in winter, appears to reduce a child’s risk for contracting acute respiratory infections by almost 50%, show results from a Mongolian study.

21 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today top-line results from a Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

31 May 2012

Researchers barcode different strains of influenza virus and HRSV

Dr Julian Hiscox and Dr John Barr of the University's Faculty of Biological Sciences are working with the Health Protection Agency Porton (HPA) to build a bank of molecular signatures that will help identify the severity of virus infection from characteristic changes seen in cells. Currently the team is barcoding different strains of influenza virus and human respiratory syncytial virus (HRSV) - a virus associated with the onset of asthma in young children.

14 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.

4 May 2012

Positive data from Synairgen’s SNG001 Phase II trial on asthma

Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.

20 Apr 2012

Needle-free vaccine shows promise against RSV in children

Researchers at the University of Saskatchewan are closing in on a needle-free vaccine for respiratory syncytial virus (RSV), a major cause of respiratory illness in children under two years of age.

30 Mar 2012

GenVec announces data from respiratory syncytial virus vaccine program

GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the "Keystone Symposium on Viral Immunity and Host Gene Influence", which is taking place in Keystone, Colorado from March 21-26, 2012.

26 Mar 2012

Extremely contagious RSV virus can lead to serious illness in young children

Respiratory Syncytial Virus (RSV) is a common virus that infects the lungs and breathing passage ways. Though it may only produce minor cold symptoms in adults, it can lead to serious illness in young children and those with compromised immune systems.

17 Mar 2012